AHA 2018

Diuretic Regimen More Effectively Reduces CV Morbidity vs Telmisartan Combinations in Hypertension With Diabetes

Diuretic Regimen More Effectively Reduces CV Morbidity vs Telmisartan Combinations in Hypertension With Diabetes

By

Previous studies on the suitability of diuretics for patients with hypertension and diabetes reveal inconsistencies.

Combination Therapy May Improve Anticoagulant Activity, Reduce Hypertensive Organ Damage

Combination Therapy May Improve Anticoagulant Activity, Reduce Hypertensive Organ Damage

By

Coagulant activity was improved with the use of both anticoagulation and antihypertensive therapies in combination.

Gender Differences in ASCVD Care, Quality of Life, and Outcomes

Gender Differences in ASCVD Care, Quality of Life, and Outcomes

By

Women with ASCVD are at an increased risk for poor patient experience, lower health-related QOL, and inferior perception of their health compared with men.

Canakinumab May Reduce CV Events in Patients Post-MI With Residual Inflammatory Risk

Canakinumab May Reduce CV Events in Patients Post-MI With Residual Inflammatory Risk

By

Canakinumab significantly reduced the total number of CV events in patients with prior MI and residual inflammatory risk.

Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)

Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)

By

AKCEA-APO(a)-LRX is efficient and safe in patients with established cardiovascular disease and elevated levels of lipoprotein(a).

CABG Vein Harvesting Techniques Have Similar MACE Risks

CABG Vein Harvesting Techniques Have Similar MACE Risks

By

In patients undergoing coronary artery bypass grafting, no significant difference was found between endoscopic and open vein graft harvesting in terms of MACE risk.

Primary Prevention With Marine Omega-3 Fatty Acids Did Not Modify MACE Risk

Primary Prevention With Marine Omega-3 Fatty Acids Did Not Modify MACE Risk

By

Supplementation with omega-3 fatty acids did not result in a lower MACE incidence compared with placebo.

Chronic CCB Therapy Linked to Improved Outcomes After CABG Utilizing the Radial Artery

Chronic CCB Therapy Linked to Improved Outcomes After CABG Utilizing the Radial Artery

By By

Mario F.L. Gaudino, MD, and colleagues evaluated whether calcium-channel blocker therapy influences clinical and angiographic outcomes of radial artery grafts used for coronary bypass surgery.

Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes

Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes

By

Dapagliflozin was not associated with either a higher or lower rate of MACE compared with placebo in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease.

Low-Dose Methotrexate Does Not Reduce Atherosclerotic Events in Stable Atherosclerosis

Low-Dose Methotrexate Does Not Reduce Atherosclerotic Events in Stable Atherosclerosis

By

Low-dose methotrexate did not result in a reduced number of cardiovascular events among patients with stable atherosclerosis.

Sacubitril-Valsartan Superior to Enalapril for Reducing NT-proBNP in HFrEF

Sacubitril-Valsartan Superior to Enalapril for Reducing NT-proBNP in HFrEF

By

A sacubitril-valsartan therapy regimen was associated with greater reductions in NT-proBNP concentrations in patients with HFrEF compared with enalapril.

AHA/ACC Release Updated Guidelines for Cholesterol Management

AHA/ACC Release Updated Guidelines for Cholesterol Management

By

Updated cholesterol guidelines offer more personalized cardiovascular disease risk assessment.

Intensive Systolic BP Control May Improve Cardiovascular Outcomes in High-Risk Patients Without CKD

Intensive Systolic BP Control May Improve Cardiovascular Outcomes in High-Risk Patients Without CKD

By

Intensive systolic blood pressure targets have cardiovascular benefits but influence the likelihood of incident chronic kidney disease (CKD) events in patients without baseline CKD.

Calcium Channel Blockers May Reduce Peripheral Arterial Disease Risk in Hypertensive Patients

Calcium Channel Blockers May Reduce Peripheral Arterial Disease Risk in Hypertensive Patients

By

Meta-analysis suggests that calcium channel blockers can be effective in preventing peripheral arterial disease in patients with hypertension.

Omega-3 Fatty Acids Reduce MACE in Mild Hypertriglyceridemia

Omega-3 Fatty Acids Reduce MACE in Mild Hypertriglyceridemia

By

In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.

Violent Crimes Associated With Larger BP Increases in Low-Crime Areas

Violent Crimes Associated With Larger BP Increases in Low-Crime Areas

An increase in blood pressure in people living in safe Chicago neighborhoods was associated with the spike of crimes committed.

ARISTOTLE: Combining NSAIDs With Oral Anticoagulants Increases Bleeding Risk in AF

ARISTOTLE: Combining NSAIDs With Oral Anticoagulants Increases Bleeding Risk in AF

By

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

Bacterial Pneumonia Associated With Increased Risk for Future MACE

Bacterial Pneumonia Associated With Increased Risk for Future MACE

By

Patients with bacterial pneumonia are at higher risk for major adverse cardiovascular events within 90 days compared with patients with viral pneumonia.

Icosapent Ethyl Reduces Ischemic Event Risk in Patients With Hypertriglyceridemia Despite Statin Use

Icosapent Ethyl Reduces Ischemic Event Risk in Patients With Hypertriglyceridemia Despite Statin Use

By

The risk for the primary composite endpoint was significantly lowered by 25% among patients who received 2g of icosapent ethyl twice daily vs those who received placebo.

Vitamin D Supplementation Does Not Lower Cardiovascular Event Incidence

Vitamin D Supplementation Does Not Lower Cardiovascular Event Incidence

By

Vitamin D supplementation did not lower the incidence of cancer or cardiovascular events compared with placebo.

Alirocumab Well-Tolerated and Effective in Patients With Statin

Alirocumab Well-Tolerated and Effective in Patients With Statin

By

Researcher observed a much lower rate of discontinuations due to skeletal muscle events with alirocumab in the open-label extension trial compared with the double-blind parent study (3.2% vs 15.9%).

Pitavastatin Plus Ezetimibe May Improve Outcomes for ACS Without Hypertension

Pitavastatin Plus Ezetimibe May Improve Outcomes for ACS Without Hypertension

By

Combined treatment with pitavastatin and ezetimibe may be beneficial in patients with acute coronary syndrome and without hypertension for secondary prevention.

Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia

Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia

By

Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.

CHA2DS2-VASc Score Accurately Predicts PCI Outcomes

CHA2DS2-VASc Score Accurately Predicts PCI Outcomes

By

Study supports CHA2DS2-VASc score as an accurate risk prediction model for patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Empagliflozin Effectively Reduces Risk for Heart Failure Hospitalization

Empagliflozin Effectively Reduces Risk for Heart Failure Hospitalization

By

Approximately 50% of deaths in people with type 2 diabetes worldwide, and approximately two-thirds of deaths in people with type 2 diabetes in the US are caused by cardiovascular disease.

Vitamin D Plus Calcium Supplementation May Not Modify Atrial Fibrillation Risk

Vitamin D Plus Calcium Supplementation May Not Modify Atrial Fibrillation Risk

By

Baseline serum 25(OH)D level was not predictive of long-term incident atrial fibrillation risk.

Rivaroxaban Has Positive Risk-Benefit Profile for Non-Valvular Atrial Fibrillation

Rivaroxaban Has Positive Risk-Benefit Profile for Non-Valvular Atrial Fibrillation

By

Rivaroxaban given at doses of both 20mg and 15mg may have an improved bleeding risk profile compared with vitamin K antagonists.

Risks vs Benefits of Routine Prophylactic Aspirin in Patients Without Known Heart Disease

Risks vs Benefits of Routine Prophylactic Aspirin in Patients Without Known Heart Disease

By

The data presented in this study support the routine use of aspirin as recommended by the USPSTF.

Use of Both Aspirin and NSAIDs Associated With Incident Heart Failure Risk

Use of Both Aspirin and NSAIDs Associated With Incident Heart Failure Risk

By

The use of both NSAID and aspirin was positively associated with incident HF in adults with no prior history of CVD.

Cardiogenic Shock Associated With Poor Clinical Outcomes in Takotsubo Syndrome

Cardiogenic Shock Associated With Poor Clinical Outcomes in Takotsubo Syndrome

By

Patients with broken heart syndrome complicated by cardiogenic shock remain at a greater risk for death years after the initial event.

Sign Up for Free e-Newsletters